African-Americans less likely to respond to direct-acting antivirals for hep-C
Last Updated: 2018-03-01
By Will Boggs MD
NEW YORK (Reuters Health) - African-Americans are less likely than other patients to achieve sustained virological response 12 weeks (SVR12) after completion of direct-acting antiviral treatment for hepatitis C virus (HCV) infection, according to a retrospective study of U.S. military veterans.
"The results may indicate that the lower response rate in African-Americans may have important underlying pathophysiological rationale and that in the treatment of these patients greater attention will need to be given to being certain that they attain a sustained virological response," Dr. Joseph R. Pisegna from David Geffen School of Medicine at UCLA, in California, told Reuters Health by email.
Last Updated: 2018-03-01
By Will Boggs MD
NEW YORK (Reuters Health) - African-Americans are less likely than other patients to achieve sustained virological response 12 weeks (SVR12) after completion of direct-acting antiviral treatment for hepatitis C virus (HCV) infection, according to a retrospective study of U.S. military veterans.
"The results may indicate that the lower response rate in African-Americans may have important underlying pathophysiological rationale and that in the treatment of these patients greater attention will need to be given to being certain that they attain a sustained virological response," Dr. Joseph R. Pisegna from David Geffen School of Medicine at UCLA, in California, told Reuters Health by email.
Continue reading: http://www.chronicliverdisease.org/reuters/article.cfm?article=20180301Other918928465
Of Interest On This Blog
A “paradigm shift” in the VA’s approach to hep C
Aim - To determine whether implementation of interferon-free treatment for hepatitis C virus (HCV) reached groups less likely to benefit from earlier therapies, including patients with genotype 1virus or contraindications to interferon treatment, and groups that faced treatment disparities: African Americans, patients with HIV co-infection, and those with drug use disorder.
Of Interest On This Blog
A “paradigm shift” in the VA’s approach to hep C
Aim - To determine whether implementation of interferon-free treatment for hepatitis C virus (HCV) reached groups less likely to benefit from earlier therapies, including patients with genotype 1virus or contraindications to interferon treatment, and groups that faced treatment disparities: African Americans, patients with HIV co-infection, and those with drug use disorder.
No comments:
Post a Comment